Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
REGN [NASD]
Regeneron Pharmaceuticals, Inc.
IndexS&P 500 P/E88.45 EPS (ttm)3.46 Insider Own1.50% Shs Outstand100.88M Perf Week-1.96%
Market Cap30.87B Forward P/E25.49 EPS next Y12.00 Insider Trans-3.33% Shs Float75.23M Perf Month7.28%
Income390.90M PEG4.31 EPS next Q2.26 Inst Own75.30% Short Float5.26% Perf Quarter-1.82%
Sales2.29B P/S13.48 EPS this Y-43.60% Inst Trans0.16% Short Ratio4.66 Perf Half Y3.49%
Book/sh22.40 P/B13.66 EPS next Y21.33% ROA13.90% Target Price345.83 Perf Year10.08%
Cash/sh6.43 P/C47.63 EPS next 5Y20.53% ROE21.30% 52W Range227.64 - 352.49 Perf YTD11.18%
Dividend- P/FCF87.95 EPS past 5Y42.20% ROI19.20% 52W High-12.55% Beta0.91
Dividend %- Quick Ratio5.90 Sales past 5Y54.60% Gross Margin89.50% 52W Low35.40% ATR8.84
Employees2389 Current Ratio6.10 Sales Q/Q42.30% Oper. Margin34.60% RSI (14)54.51 Volatility2.55% 3.08%
OptionableYes Debt/Eq0.24 EPS Q/Q-35.60% Profit Margin17.10% Rel Volume1.02 Prev Close306.02
ShortableYes LT Debt/Eq0.24 EarningsAug 05 BMO Payout0.00% Avg Volume849.93K Price308.23
Recom2.10 SMA202.17% SMA502.27% SMA2003.48% Volume248,492 Change0.72%
21-Jul-14Initiated Argus Buy $375
16-Apr-14Initiated Canaccord Genuity Buy $350
13-Feb-14Downgrade Oppenheimer Outperform → Perform $310 → $325
30-Sep-13Reiterated Oppenheimer Outperform $300 → $310
22-Aug-13Initiated Oppenheimer Outperform $300
17-May-13Initiated UBS Neutral $290
06-May-13Reiterated RBC Capital Mkts Outperform $270 → $286
06-May-13Reiterated Barclays Overweight $275 → $305
02-May-13Reiterated Barclays Overweight $194 → $275
28-Feb-13Initiated Barclays Overweight $194
21-Dec-12Reiterated RBC Capital Mkts Outperform $171 → $190
14-Feb-12Reiterated RBC Capital Mkts Outperform $83 → $130
10-Jan-12Upgrade Robert W. Baird Neutral → Outperform $56 → $81
05-Dec-11Reiterated Brean Murray Buy $78 → $67
28-Jul-11Upgrade RBC Capital Mkts Sector Perform → Outperform $70 → $70
09-May-11Reiterated Needham Buy $49 → $60
29-Apr-11Reiterated Barclays Capital Overweight $64 → $72
29-Apr-11Downgrade RBC Capital Mkts Outperform → Sector Perform $70 → $70
28-Apr-11Reiterated RBC Capital Mkts Outperform $48 → $70
28-Apr-11Reiterated Brean Murray Buy $67 → $78
23-Jul-14 10:54AM  Biogen Idec: Biggest Beat in 10 Years, Largest Leap in Eight Months at Barrons.com
22-Jul-14 04:20PM  Bayer/Regeneron Continue to Progress with Eylea Zacks
21-Jul-14 09:32AM  Coverage initiated on Regeneron Pharms by Argus Briefing.com
18-Jul-14 04:01PM  Regeneron to Report Second Quarter 2014 Financial and Operating Results and Host Conference Call and Webcast on August 5, 2014 PR Newswire
12:41PM  Gilead Sciences: Time For a Dividend? at Barrons.com
10:28AM  InsiderInsights.com Daily Round Up: 7/17/14 at Seeking Alpha
06:00AM  Two-Year Results From Phase 3 VIVID-DME Trial of EYLEA® (aflibercept) Injection for the Treatment of Diabetic Macular Edema Show Sustained Improvement in Vision PR Newswire
16-Jul-14 01:04PM  SHPG, REGN And LLY, 3 Drugs Stocks Pushing The Industry Lower at TheStreet
15-Jul-14 12:22PM  InsiderInsights.com Daily Round Up: 7/14/14 at Seeking Alpha
11-Jul-14 03:06PM  Gilead Sciences: The Senate Just Wrote Me a Letter at Barrons.com
10-Jul-14 03:30PM  Sanofi/Regeneron Announce Encouraging Dupilumab Data Zacks
01:46PM  Regeneron's Dupilumab Drug Headed For Phase Three Tests at Investor's Business Daily
10:07AM  Regeneron Picked a Heck of a Day to Announce Good News at Barrons.com
08:20AM  The Zacks Analyst Blog Highlights: Regado Biosciences, Jazz Pharmaceuticals, Regeneron Pharmaceuticals, Sanofi and Amgen Zacks
06:27AM  Cramer's Mad Money - The 4 Horsemen Of Biotech Ride On (7/9/14) at Seeking Alpha
06:00AM  Jim Cramer's Top Stock Picks: WMB AA BIIB REGN CELG GILD UNUM at TheStreet
05:35AM  Valeant Is Hard to Stop TheStreet
09-Jul-14 09:04PM  Regeneron, Sanofi Drug Holds Up in Eczema Study at Motley Fool
07:30PM  Jim Cramer's 'Mad Money' Recap: Hunting for Bargains at TheStreet
06:59PM  Jim Cramer's 'Mad Money' Recap: Hunting for Bargains at TheStreet
06:29PM  Cramer: 4 strong stocks for months to come at CNBC
06:25PM  [video] Four horseman of biotech have a lot of upside: Cramer at CNBC
05:53PM  In Trials, 2 Drugs Soothe Eczema and Psoriasis at New York Times
05:53PM  In Small Trials, 2 Drugs Go Far in Soothing Symptoms of Eczema and Psoriasis at New York Times
05:53PM  Drugs Show Promise in Soothing Eczema and Psoriasis in Trials at New York Times
05:20PM  [$$] Regeneron, Sanofi to Begin Eczema Drug Study at The Wall Street Journal
05:00PM  Sanofi-Regeneron drug tames eczema in study Reuters
05:00PM  Sanofi Plans Final Tests as Regeneron Drug Cuts Eczema Symptoms at Bloomberg
05:00PM  Regeneron and Sanofi Announce Positive Results from Phase 2b Study of Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis PR Newswire
11:10AM  Anacor's Kerydin Gets FDA Nod for Onychomycosis Zacks
10:09AM  Sanofi Is Buying Shares Of Regeneron - You Should Too at Seeking Alpha
09:30AM  Drugmakers criticise French move to back cheap off-label eye treatment Reuters
08-Jul-14 05:04PM  Is Opthotech Your Next Multibagger Stock? at Motley Fool
10:04AM  French lawmakers back Roche cancer drug as cheap eye treatment Reuters
07-Jul-14 05:02PM  Growth and Dividends: Europe's Best Pharma Stock at Motley Fool
04:20PM  Hospira Completes Orchid Facility Buy Zacks
03:00PM  Spectrum Pharmaceuticals Gains U.S. Approval of Beleodaq Zacks
06-Jul-14 03:00PM  3 Stocks That Soared Stupendously This Week at Motley Fool
03-Jul-14 02:02PM  Regeneron's $4.7 Billion Opportunity at Motley Fool
12:50PM  RedHill Acquires Mesupron from Wilex Zacks
12:38PM  Gilead Sciences: Time for an Earnings Beat? at Barrons.com
11:58AM  Midday movers: Lorillard, PetSmart, Walgreen & More at CNBC
02-Jul-14 03:51PM  GlycoMimetics Up on FDA Agreement on Rivipansel Study Zacks
02:51PM  Wednesday Sector Leaders: Healthcare, Services at Forbes
11:10AM  Roche Acquires Seragon Pharma Zacks
10:30AM  Regeneron Shares Jump as Sanofi Increases Stake Zacks
09:41AM  Biotech Stock Roundup: Vertex Jumps on Phase III Data, MannKind Scores FDA Approval Zacks
09:24AM  Stock Downgrades: Monty Python Is Back, but Hormel Foods Finds We Still Don't Like Spam a Lot at Minyanville
08:18AM  Regeneron Pharmaceuticals (REGN) Jumps: Stock Gains 7.4% Zacks
06:06AM  Cramer's Mad Money - The Mother Of All Speculative Stocks (7/1/14) at Seeking Alpha
01-Jul-14 06:15PM  Why 3D Systems, Arista Networks, and Regeneron Pharmaceuticals Jumped Today at Motley Fool +7.41%
06:08PM  Cramer: Six buyable themes in second half at CNBC
06:08PM  Cramer: 6 buyable themes in second half at CNBC
05:19PM  Salix Pharma Hits A New High On Bullish Clinical-Trial Data Investor's Business Daily
05:11PM  ESC Hot Lines: First Real Data On Promising Novartis Heart Failure Drug at Forbes
04:22PM  Netflix and Twitter are big market movers AP
03:45PM  Amicus Up on Migalastat Study Update Zacks
02:47PM  Tuesday Sector Leaders: Healthcare, Technology & Communications at Forbes
01:22PM  Stocks Rise In Strong Turnover; Netflix Soars On Upgrade at Investor's Business Daily
01:12PM  Regeneron Rises As Sanofi Raises Stake In Biotech at Investor's Business Daily
01:09PM  Why Regeneron Pharmaceuticals (REGN) Stock Is Soaring Today at TheStreet
12:34PM  On The Fly: Midday Wrap at theflyonthewall.com
11:00AM  Roche Launches cobas 6500 Testing System Zacks
10:45AM  Regeneron Pharmaceuticals (REGN) Is Today's Storm The Castle Stock at TheStreet
10:30AM  NPS Pharmaceuticals' Gattex Gets Updated Label Zacks
09:07AM  [$$] Sanofi Adds to Regeneron Stake at The Wall Street Journal
30-Jun-14 03:10PM  MannKind's Afrezza Approval a Key Milestone Zacks
01:51PM  US FDA delays Allergan migraine drug approval, OKs new eye drug use Reuters
12:50PM  Eli Lilly & Boehringer's Insulin Copy Gets Positive EU Opinion Zacks
12:40PM  Vertex Pharmaceuticals' Kalydeco Wins Positive EU Opinion Zacks
28-Jun-14 11:45AM  Phase II Calamity Dooms Ohr's Eye Drops at Seeking Alpha
27-Jun-14 02:40PM  Friday Sector Laggards: Materials, Healthcare at Forbes
02:40PM  Friday Sector Laggards: Materials, Healthcare
11:50AM  Bristol-Myers, Pfizer, Regeneron Drugs Get EU Nods at Investor's Business Daily
11:50AM  Bristol-Myers, Pfizer, Regeneron Drugs Get EU Nods
07:41AM  Bayer's Stivarga endorsed for gastrointestinal stromal tumors Reuters
07:41AM  Bayer's Stivarga endorsed for gastrointestinal stromal tumors
07:17AM  EYLEA® (aflibercept) Injection Recommended for Approval for the Treatment of Visual Impairment due to Diabetic Macular Edema in the European Union PR Newswire
07:17AM  EYLEA® (aflibercept) Injection Recommended for Approval for the Treatment of Visual Impairment due to Diabetic Macular Edema in the European Union
26-Jun-14 12:09PM  Auxilium Acquiring QLT For New Products, Low Taxes at Investor's Business Daily
12:09PM  Auxilium Acquiring QLT For New Products, Low Taxes
24-Jun-14 05:20PM  Forest Laboratories Reports Positive Data on Viibryd
03:55PM  XenoPort's XP23829 in Phase II Study
12:07PM  Ohr Pharma Applies a Ton of Lipstick to Squalamine Pig at TheStreet
12:07PM  Ohr Pharma Applies a Ton of Lipstick to Squalamine Pig
10:40AM  Clovis Oncology Initiates Study on CO-1686
01:06AM  General Electric Falls as the Dow Drops Back at Motley Fool
01:06AM  General Electric Falls as the Dow Drops Back
23-Jun-14 03:45PM  Merrimack Falls Steeply as Sanofi Returns Oncology Drug Rights
01:29PM  Major Indexes Narrowly Lower As Actavis Rallies at Investor's Business Daily
01:29PM  Major Indexes Narrowly Lower As Actavis Rallies
01:18PM  [video] How Vertex's breakthrough helps cystic fibrosis patients at CNBC
01:18PM  [video] How Vertex's breakthrough helps cystic fibrosis patients
01:18PM  [video] Big event coming in biotech
20-Jun-14 11:34AM  Midday movers: Alstom, CarMax, Sprint & More at CNBC
11:34AM  Midday movers: Alstom, CarMax, Sprint & More
10:00AM  Cubist Gets Priority Review from FDA for Antibiotic Candidate Zacks
10:00AM  Cubist Gets Priority Review from FDA for Antibiotic Candidate
19-Jun-14 05:10PM  BioLineRx to Commence BL-8040 Study Zacks
03:18PM  Roof Leaker To Watch: Regeneron Pharmaceuticals (REGN) at TheStreet
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. The company offers EYLEA injection for the treatment of neovascular age-related macular degeneration and macular edema; ZALTRAP, an injection for intravenous infusion for the treatment of patients with metastatic colorectal cancer; and ARCALYST, an injection for subcutaneous use for treating cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and children. Its product candidates in clinical development stage comprise EYLEA for the treatment of DME and macular edema ophthalmologic diseases; and ZALTRAP for oncology. The company's antibody-based clinical programs include various human monoclonal antibody product candidates, such as REGN88 for rheumatoid arthritis and non-infectious uveitis; REGN727 for low-density lipoprotein cholesterol reduction; REGN668 for atopic dermatitis, asthma, and nasal polyposis; REGN421, REGN910, and REGN1400 for oncology; REGN475 for the treatment of pain; and REGN1033 for skeletal muscle disorders. It is also developing REGN1154, REGN1154, REGN1193, and REGN1908-1909 antibody product candidates, as well as REGN2176-3, an antibody that is co-formulated with EYLEA for use in ophthalmology. The company distributes its products through Rensselaer facilities and third party service providers. It has strategic collaboration with Sanofi to discover, develop, and commercialize human monoclonal antibodies; and license and collaboration agreement with Bayer HealthCare for the development and commercialization of EYLEA outside the United States. The company was founded in 1988 and is headquartered in Tarrytown, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Van Plew Daniel PSVP & General Mgr Industrial OMay 23Sale295.935,3691,588,87215,441May 23 03:58 PM
Van Plew Daniel PSVP & General Mgr Industrial OMay 22Option Exercise21.2511,200238,00026,641May 23 03:58 PM
POON CHRISTINE ADirectorMay 21Buy291.9025574,435255May 23 10:43 AM
BAKER CHARLES ADirectorMar 24Option Exercise23.8415,000357,60024,000Mar 25 08:03 PM
BAKER CHARLES ADirectorMar 24Sale302.6715,0004,540,0019,000Mar 25 08:03 PM
BROWN MICHAEL SDirectorMar 17Option Exercise33.422,00066,84016,662Mar 18 05:09 PM
BROWN MICHAEL SDirectorMar 17Sale334.292,000668,57314,662Mar 18 05:09 PM
VAGELOS P ROYChairman of the BoardFeb 27Option Exercise12.7070,879899,952140,839Mar 03 09:10 AM
BROWN MICHAEL SDirectorFeb 27Sale335.001,000335,00014,662Feb 27 04:30 PM
BROWN MICHAEL SDirectorFeb 26Option Exercise57.111,00057,11015,662Feb 27 04:30 PM
GOLDSTEIN JOSEPH LDirectorFeb 25Sale338.861,000338,8600Feb 25 05:48 PM
GOLDBERG MURRAY ASVP Administration & Asst SecrFeb 25Sale339.5511,8714,030,82363,102Feb 26 04:57 PM
GOLDBERG MURRAY ASVP Administration & Asst SecrFeb 24Option Exercise64.9030,2271,961,74685,365Feb 26 04:57 PM
GILMAN ALFRED GDirectorFeb 21Option Exercise18.615,00093,0505,000Feb 24 04:12 PM
SING GEORGE LDirectorFeb 21Option Exercise15.8015,000237,000117,772Feb 24 04:12 PM
SING GEORGE LDirectorFeb 21Sale339.0015,0005,085,000112,772Feb 24 04:12 PM
GILMAN ALFRED GDirectorFeb 21Sale340.005,0001,700,0000Feb 24 04:12 PM
GOLDBERG MURRAY ASVP Administration & Asst SecrFeb 21Sale336.5121,2587,153,60863,102Feb 24 04:11 PM
GOLDBERG MURRAY ASVP Administration & Asst SecrFeb 20Option Exercise47.7950,6522,420,80593,102Feb 24 04:11 PM
McCorkle Douglas SVP Controller and Asst TreasurFeb 20Option Exercise21.253,00063,7503,000Feb 21 04:43 PM
GOLDSTEIN JOSEPH LDirectorFeb 20Sale326.991,000326,9891,000Feb 21 04:44 PM
Terifay Robert JSVP CommercialFeb 18Sale332.6812,8654,279,89320,029Feb 19 04:10 PM
Aberman Michael SVP Strategy and Investor RelatFeb 18Sale331.423,6481,209,03615,600Feb 19 04:12 PM
Aberman Michael SVP Strategy and Investor RelatFeb 14Option Exercise30.637,500229,72523,100Feb 19 04:12 PM
SING GEORGE LDirectorFeb 14Option Exercise9.1715,000137,550127,772Feb 19 04:11 PM
Terifay Robert JSVP CommercialFeb 14Option Exercise21.2527,795590,64447,824Feb 19 04:10 PM
SING GEORGE LDirectorFeb 14Sale324.0015,0004,860,000112,772Feb 19 04:11 PM
STAHL NEILSVP Research and Development SFeb 13Sale318.8222,6127,209,13624,391Feb 13 06:32 PM
SHOOTER ERIC MDirectorFeb 12Option Exercise89.4515,0001,341,75015,000Feb 13 07:38 PM
STAHL NEILSVP Research and Development SFeb 12Option Exercise20.0654,5481,094,40664,391Feb 13 06:32 PM
SHOOTER ERIC MDirectorFeb 12Sale320.5215,0004,807,8690Feb 13 07:38 PM
GOLDSTEIN JOSEPH LDirectorFeb 12Sale320.621,000320,6202,000Feb 13 04:06 PM
YANCOPOULOS GEORGEPresident Regeneron LaboratoriFeb 12Sale320.3388,98728,504,9851,068,343Feb 13 04:03 PM
YANCOPOULOS GEORGEPresident Regeneron LaboratoriFeb 11Option Exercise9.49189,4631,798,0041,257,806Feb 13 04:03 PM
McCorkle Douglas SVP Controller and Asst TreasurFeb 11Option Exercise30.635,819178,2365,819Feb 12 04:15 PM
GILMAN ALFRED GDirectorFeb 11Option Exercise18.615,00093,0505,000Feb 12 04:17 PM
McCorkle Douglas SVP Controller and Asst TreasurFeb 11Sale325.005,8191,891,1750Feb 12 04:15 PM
VAGELOS P ROYChairman of the BoardFeb 11Sale325.1011,4753,730,523103,275Feb 12 04:15 PM
GILMAN ALFRED GDirectorFeb 11Sale320.005,0001,600,0000Feb 12 04:17 PM
GILMAN ALFRED GDirectorJan 14Option Exercise18.615,00093,0505,000Jan 14 05:25 PM
McCorkle Douglas SVP Controller and Asst TreasurJan 14Sale290.004,0001,160,0000Jan 14 05:26 PM
GILMAN ALFRED GDirectorJan 14Sale300.005,0001,500,0000Jan 14 05:25 PM
Powchik PeterSVP Clinical Development & RegJan 02Sale274.7720,6685,678,96525,447Jan 03 04:10 PM
Powchik PeterSVP Clinical Development & RegDec 31Option Exercise30.6348,0001,470,24073,447Jan 03 04:10 PM
Powchik PeterSVP Clinical Development & RegDec 24Option Exercise21.254,70599,98125,447Dec 26 01:26 PM
Powchik PeterSVP Clinical Development & RegDec 20Sale271.0913336,05520,742Dec 20 05:54 PM
YANCOPOULOS GEORGEPresident Regeneron LaboratoriDec 19Option Exercise21.254,70599,9811,068,343Dec 20 05:54 PM
STAHL NEILSVP Research and Development SDec 18Option Exercise21.254,70599,98124,391Dec 19 09:49 PM
GOLDBERG MURRAY ASVP Administration & Asst SecrDec 18Option Exercise21.254,70599,98163,102Dec 19 09:49 PM
Van Plew Daniel PSVP & General Mgr Industrial ODec 18Option Exercise21.254,70599,98115,441Dec 19 09:48 PM
Terifay Robert JSVP CommercialDec 18Option Exercise21.254,70599,98120,029Dec 19 09:48 PM
Powchik PeterSVP Clinical Development & RegDec 18Option Exercise21.252956,26921,037Dec 20 05:54 PM
Powchik PeterSVP Clinical Development & RegDec 18Sale270.209,0002,431,80020,742Dec 20 05:54 PM
Powchik PeterSVP Clinical Development & RegDec 17Sale270.0082,16029,742Dec 17 04:16 PM
Powchik PeterSVP Clinical Development & RegDec 16Option Exercise107.1430,6253,281,05638,503Dec 17 04:16 PM
YANCOPOULOS GEORGEPres Regeneron LabsDec 12Option Exercise260.449,5992,499,9641,115,994Dec 13 04:29 PM
VAGELOS P ROYChairman of the BoardDec 02Sale296.119528,1302,257Dec 04 07:34 PM
SING GEORGE LDirectorNov 26Option Exercise15.0110,000150,100122,772Nov 27 04:22 PM
SING GEORGE LDirectorNov 26Sale295.0010,0002,950,000112,772Nov 27 04:22 PM
GOLDSTEIN JOSEPH LDirectorNov 06Sale300.741,000300,7403,000Nov 06 04:17 PM
SCHLEIFER LEONARD SPresident & CEOOct 02Sale313.829,1622,875,25342,087Oct 03 04:14 PM
SCHLEIFER LEONARD SPresident & CEOOct 01Option Exercise111.0129,2763,249,92969,562Oct 03 04:14 PM
BAKER CHARLES ADirectorSep 30Option Exercise19.6915,000295,35024,000Oct 02 04:23 PM
BAKER CHARLES ADirectorSep 30Sale314.0315,0004,710,4399,000Oct 02 04:23 PM
BROWN MICHAEL SDirectorSep 26Option Exercise33.425,000167,10019,662Sep 27 04:07 PM
BROWN MICHAEL SDirectorSep 26Sale309.005,0001,545,00014,662Sep 27 04:07 PM
BROWN MICHAEL SDirectorSep 25Option Exercise33.425,000167,10019,662Sep 27 04:07 PM
BROWN MICHAEL SDirectorSep 25Sale293.645,0001,468,22214,662Sep 27 04:07 PM
SCHLEIFER LEONARD SPresident & CEOSep 19Sale302.67102,94931,159,18142,087Sep 20 04:25 PM
ROBERTS WILLIAMVP Reg Dev & Med SafetySep 18Option Exercise16.8015,000252,00035,644Sep 20 04:24 PM
SCHLEIFER LEONARD SPresident & CEOSep 18Option Exercise9.49218,3892,072,512260,476Sep 20 04:25 PM
ROBERTS WILLIAMVP Reg Dev & Med SafetySep 18Sale304.0015,0004,560,00020,644Sep 20 04:24 PM
Van Plew Daniel PSVP & Gen Mgr IOPSSep 18Sale303.1723,9777,269,04210,736Sep 19 05:16 PM
Van Plew Daniel PSVP & Gen Mgr IOPSSep 17Option Exercise16.8052,500882,00063,236Sep 19 05:16 PM
SCHLEIFER LEONARD SCEO & PresidentSep 09Sale275.475,0001,377,3320Sep 11 04:05 PM
GOLDSTEIN JOSEPH LDirectorAug 23Sale238.291,000238,2904,000Aug 23 05:32 PM
RYAN ARTHUR FDirectorAug 23Sale238.4710,9582,613,15449,855Aug 26 10:26 AM
RYAN ARTHUR FDirectorAug 22Option Exercise31.9030,000956,90062,019Aug 26 10:26 AM
GOLDBERG MURRAY ASVP Finance and Admin CFO andAug 01Option Exercise16.805,00084,00063,554Aug 02 11:37 AM